STOCK TITAN
  1. Home
  2. Sec-filings
  3. JAGX
  4. [Form 4] Jaguar Health, Inc. Insider Trading Activity

Jaguar Health, Inc. (JAGX) director granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jaguar Health director James J. Bochnowski reported new equity awards. On December 11, 2025, he received 6,363 restricted stock units and a stock option for 6,363 shares of common stock, granted under the company’s 2014 Stock Incentive Plan.

Each restricted stock unit represents one share of voting common stock and will vest on December 11, 2026, with shares delivered on that date. The stock option has an exercise price of $1.44 per share, vests ratably on a monthly basis over 12 months from the grant date while he continues serving on the board, and expires on December 11, 2035.

Following the grant, Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.

Positive

  • None.

Negative

  • None.
Insider BOCHNOWSKI JAMES J
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 6,363 $0.00 --
Grant/Award Common Stock 6,363 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 6,363 shares (Direct); Common Stock — 6,415 shares (Direct)
Footnotes (1)
  1. Granted pursuant to the issuer's 2014 Stock Incentive Plan. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOCHNOWSKI JAMES J
(Last) (First) (Middle)
C/O JAGUAR HEALTH, INC.
200 PINE ST., STE 400
(Street)
SAN FRANCISCO CA 94104
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Jaguar Health, Inc. [ JAGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock(1) 12/11/2025(2)(3) A 6,363 A $0 6,415(4)(5) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)(1) $1.44 12/11/2025(2) A 6,363 (6) 12/11/2035 Common Stock 6,363 $0 6,363 D
Explanation of Responses:
1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.
2. The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
3. Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
4. On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
5. On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
6. The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer.
/s/ James J. Bochnowski 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Jaguar Health (JAGX) report for its director?

The filing shows director James J. Bochnowski received 6,363 restricted stock units and a stock option for 6,363 shares of Jaguar Health common stock on December 11, 2025.

What are the key terms of the stock options granted to the Jaguar Health director?

The stock option covers 6,363 shares of common stock with an exercise price of $1.44 per share, was granted on December 11, 2025, and expires on December 11, 2035.

How do the restricted stock units (RSUs) for Jaguar Health (JAGX) vest?

Each RSU represents a right to receive one share of voting common stock, and all 6,363 RSUs vest on December 11, 2026, with shares delivered on that vesting date.

What is the vesting schedule for the Jaguar Health director’s stock options?

The options vest ratably on a monthly basis over 12 months from the December 11, 2025 grant date, as long as the director continues to serve on Jaguar Health’s board.

How many Jaguar Health shares does the director beneficially own after this transaction?

After the reported grants, James J. Bochnowski beneficially owned 6,415 shares of Jaguar Health common stock directly.

Under which plan were the Jaguar Health equity awards granted?

The restricted stock units and stock options were granted under Jaguar Health’s 2014 Stock Incentive Plan.

What past corporate actions affecting Jaguar Health stock are referenced in the filing?

The filing notes a 60-for-1 reverse stock split effective May 23, 2024, and a 25-for-1 reverse stock split effective March 24, 2025, affecting issued and outstanding shares of voting common stock.